7TM Pharma Initiates Phase II Clinical Study with the Drug Candidate Obinepitide for the Treatment of Obesity

7TM Pharma has initiated a Phase II clinical study of Obinepitide (TM30338), which is being developed for the treatment of obesity and related diseases. The drug candidate is a close analogue of two natural hormones, each with different mechanisms of action, which are incorporated into one compound, Obinepitide.

Back to news